Royal Bank of Canada »

Karyopharm Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Karyopharm Therapeutics (KPTI) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Karyopharm Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2025-09-30 $44k 6.7k 6.58
2025-06-30 $32k 7.4k 4.33
2025-03-31 $5.1k 1.5k 3.51

More positions owned by Royal Bank of Canada

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Amazon (AMZN)
Toronto Dominion Bk Ont Com New (TD)
Rbc Cad (RY)
Bank Of Montreal Cadcom (BMO)
Bk Nova Cad (BNS)
Alphabet Cap Stk Cl A (GOOGL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
JPMorgan Chase & Co. (JPM)
Broadcom (AVGO)
Ishares Tr Russell 2000 Etf (IWM)

View all positions for Royal Bank of Canada

Top funds holding Karyopharm Therapeutics

T. Rowe Price Investment Management
Adage Capital Partners GP
Vanguard Group
Susquehanna International
BlackRock
Affinity Asset Advisors
Catalio Capital Management
Avidity Partners Management
Marshall Wace
CAM Group Holding A/S
Geode Capital Management
Citadel Advisors
Group One Trading
Renaissance Technologies
UBS Group

View all funds holding Karyopharm Therapeutics